193 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
in the future will be incurred in support of our current and future preclinical and clinical development projects. Due to the inherently unpredictable nature
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good … as if such payment had not been made or such enforcement or setoff had not occurred.
5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair
6-K
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
also contains representations, warranties, indemnification and other provisions customary for transactions of this nature.
JonesTrading
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
market, the liquidity of the pre-funded warrants will be limited.
The warrants are speculative in nature.
The warrants do not confer any rights … loss of the purchase price of their warrants. This risk reflects the nature of a warrant as an asset that, other factors held constant, tends
20-F/A
eli 6qbb0wog
26 Mar 24
Annual report (foreign) (amended)
4:57pm
F-3
ngkm08gzv0zd1a
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
3x3ahst60g1fbg2296
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
fwr 0khocbqad
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
jpepkcgby6
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
b3rgf5fru9 ssd10
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
t4a1y1w33ighfxu5onbg
30 Aug 23
Current report (foreign)
6:45am
6-K
vcmjlfkn
8 Aug 23
Current report (foreign)
5:25pm
6-K
EX-99
e5dp65v go0inzn
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
2ged5ifv918
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
508bq5m93kl25v
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
z3xa3zzxv k7s
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
c2jnunjdqdivbu
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
iv1b93 siwozq
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am